Crossmark

Comparative clinical trial of Langenlianqiao oral liquid and Lianhuaqingwen capsule in the treatment of mild cases of coronavirus disease 2019 (COVID-19)

Crossref DOI link: https://doi.org/10.1186/s41043-024-00649-6

Published Online: 2024-10-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Yang, Yan-Mo

Li, Qin-Xuan

Liu, Yi-Zhao

Zhou, Mi
License Information

Text and Data Mining valid from 2024-10-12

Version of Record valid from 2024-10-12
More Information

Article History

Received: 6 December 2023

Accepted: 27 September 2024

First Online: 12 October 2024

Declarations

:

: This study was conducted in accordance with the Declaration of Helsinki and approved by the ethics committee of Changde Hospital (ethical batch number: YX-2023-119-01), and informed consent was obtained from all participants.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below